Cradle’s generative platform will now sit at the center of Hansa’s early-stage research. The drugmaker is hunting new immunomodulatory therapies for autoimmune conditions.
Hansa is based in Sweden and listed on Nasdaq Stockholm. The company’s flagship therapy, imlifidase, already sells in Europe as Idefirix. The FDA is reviewing it for transplant candidates who are highly sensitized, with a ruling due in December.
According to Hansa research chief Sofia Jarnum, the company compared multiple AI vendors. Cradle won on two counts, she said: coverage of the full discovery journey, and a system that grows with the scientists who use it.
Cradle says its system optimizes multiple protein properties at once – activity, stability and expression – rather than one at a time, balancing competing goals in a single round. It runs tens of thousands of simulations to design experimental plates that mix known winning variants with new possibilities.
The company reports 2x to 12x speedups across more than 50 programs, with scientists rating its AI-engineered candidates 8 out of 10. Cradle CEO Stef van Grieken said the goal is to empower scientists with a platform rather than replace their judgment.
